We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Beyondspring Inc
14 own
16 watching
Current Price
$2.61
$0.03
(1.16%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
101.6M
52-Week High
3.4
52-Week Low
0.542
Average Volume
0.2M
Dividend Yield
--
P/E Ratio
--
Market Capitalization101.6M52-Week High3.452-Week Low0.542Average Volume0.2MDividend Yield--P/E Ratio--What does the Beyondspring Inc do?
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Read More
News & Events about Beyondspring Inc.
Globe Newswire
1month ago
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxelIn an analysis of breast cancer patients, plinabulin monotherapy was superior vs no treatment for...
PR Newswire
7 months ago
Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring? Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring? PR Newswire NEW YORK, June 10, 2022 NEW YORK, June 10, 2022 /PRNewswire/ --InvestorsObserverissues critical...
Globe Newswire
8 months ago
NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced...
Globe Newswire
8 months ago
Paul Friel
Elevar Therapeutics today announced the hiring of Paul Friel as chief commercial officer.
SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who ...
Globe Newswire
9 months ago
NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today ...
Frequently Asked Questions
Frequently Asked Questions
What is Beyondspring Inc share price today?
Can Indians buy Beyondspring Inc shares?
How can I buy Beyondspring Inc shares from India?
Can Fractional shares of Beyondspring Inc be purchased?
What are the documents required to start investing in Beyondspring Inc stocks?
What is today’s traded volume of Beyondspring Inc?
What is today’s market capitalisation of Beyondspring Inc?
What is the 52-Week High and Low Range of Beyondspring Inc?
What percentage is Beyondspring Inc down from its 52-Week High?
What percentage is Beyondspring Inc up from its 52-Week Low?
Current Price
$2.61
$0.03
(1.16%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.